title: Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation.
abstract: Multiple myeloma (MM) is usually characterized by production of a single serum monoclonal protein of constant isotype and light-chain restriction. Multiple Ig isotypes and isotype switches, which are rare in untreated patients, are reported to be more common in patients undergoing myeloablative therapy. These additional protein bands, detected by immunofixation electrophoresis (IFE), could be due to altered paraprotein production by the malignant plasma cell clone or oligoclonal Ig production during recovery of B-cell function after myeloablative therapy. We analyzed abnormal protein bands (APB), distinct from the presenting paraprotein, in 550 patients receiving high-dose therapy with autologous hematopoietic cell transplantation at a single institution. Fifty-five patients (10%) had APB, 48 had oligoclonal bands (OB), and 23 had an apparent isotype switch (IS) on IFE (16 had both OB and IS). Morphologic and flow cytometric examination of bone marrow in 17 patients with IS showed no evidence of a clonal plasma cell isotype switch. Patients with APB had significantly higher complete response to therapy (67% v 37%, P = .001). To assess the independent prognostic relevance of APB, a multivariate analysis was performed among 471 patients surviving at least 12 months from first transplant (all patients developing APB had done so by 12 months from first transplant). APB (in 50 patients) was a favorable feature for both event-free (rank 3, P = .004) and overall survival (rank 3, P = .0005). We propose that OB and IS are likely to be due to recovery of Ig production rather than alterations in the biology of the malignant plasma cell clone.
authors.affiliation: Division of Hematology/Oncology and Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors.forename: C S
authors.initials: CS
authors.lastname: Zent
authors.forename: C S
authors.initials: CS
authors.lastname: Wilson
authors.forename: G
authors.initials: G
authors.lastname: Tricot
authors.forename: S
authors.initials: S
authors.lastname: Jagannath
authors.forename: D
authors.initials: D
authors.lastname: Siegel
authors.forename: K R
authors.initials: KR
authors.lastname: Desikan
authors.forename: N
authors.initials: N
authors.lastname: Munshi
authors.forename: D
authors.initials: D
authors.lastname: Bracy
authors.forename: B
authors.initials: B
authors.lastname: Barlogie
authors.forename: A W
authors.initials: AW
authors.lastname: Butch
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D001854:Bone Marrow Cells / Q000473:pathology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007132:Immunoglobulin Isotypes / Q000378:metabolism*; D009101:Multiple Myeloma / Q000276:immunology / Q000473:pathology*; D010265:Paraproteinemias / Q000473:pathology*; D012189:Retrospective Studies; D013997:Time Factors; D014182:Transplantation, Autologous
chemical_list: D000970:Antineoplastic Agents; D007132:Immunoglobulin Isotypes